Richard Law
Stock Analyst at Goldman Sachs
(1.85)
# 3,045
Out of 4,734 analysts
52
Total ratings
24%
Success rate
0.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLTX MoonLake Immunotherapeutics | Upgrades: Buy | $62 → $82 | $45.82 | +78.96% | 2 | Jan 17, 2025 | |
| MRUS Merus | Initiates: Buy | $73 | $39.74 | +83.69% | 1 | Nov 21, 2024 | |
| CLDX Celldex Therapeutics | Initiates: Neutral | $45 | $24.61 | +82.85% | 1 | Sep 30, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $25 → $31 | $18.41 | +68.39% | 2 | Sep 12, 2024 | |
| MLYS Mineralys Therapeutics | Initiates: Buy | $30 | $9.77 | +207.06% | 5 | Apr 2, 2024 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $24 | $5.50 | +336.36% | 4 | Apr 2, 2024 | |
| RCKT Rocket Pharmaceuticals | Initiates: Neutral | $39 | $10.16 | +283.86% | 1 | Apr 2, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Neutral | $11 | $5.69 | +93.32% | 4 | Aug 11, 2023 | |
| VERV Verve Therapeutics | Reiterates: Neutral | $31 | $6.57 | +371.84% | 2 | Aug 11, 2023 | |
| BEAM Beam Therapeutics | Maintains: Neutral | $46 → $47 | $24.53 | +91.60% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $41.51 | +51.77% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $43.70 | -15.33% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $9.94 | +664.59% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $1.21 | +1,057.02% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $18.57 | +228.49% | 4 | May 8, 2023 |
MoonLake Immunotherapeutics
Jan 17, 2025
Upgrades: Buy
Price Target: $62 → $82
Current: $45.82
Upside: +78.96%
Merus
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $39.74
Upside: +83.69%
Celldex Therapeutics
Sep 30, 2024
Initiates: Neutral
Price Target: $45
Current: $24.61
Upside: +82.85%
Viridian Therapeutics
Sep 12, 2024
Maintains: Buy
Price Target: $25 → $31
Current: $18.41
Upside: +68.39%
Mineralys Therapeutics
Apr 2, 2024
Initiates: Buy
Price Target: $30
Current: $9.77
Upside: +207.06%
Olema Pharmaceuticals
Apr 2, 2024
Initiates: Buy
Price Target: $24
Current: $5.50
Upside: +336.36%
Rocket Pharmaceuticals
Apr 2, 2024
Initiates: Neutral
Price Target: $39
Current: $10.16
Upside: +283.86%
Monte Rosa Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $5.69
Upside: +93.32%
Verve Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $31
Current: $6.57
Upside: +371.84%
Beam Therapeutics
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $24.53
Upside: +91.60%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $41.51
Upside: +51.77%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $43.70
Upside: -15.33%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $9.94
Upside: +664.59%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $1.21
Upside: +1,057.02%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $18.57
Upside: +228.49%